Sacituzumab govitecan may be effective second-line option in small cell lung cancer
Click Here to Manage Email Alerts
Key takeaways:
- Sacituzumab govitecan may be an effective second-line therapy in small cell lung cancer.
- The study is ongoing and more results will be released in the next year.
MADRID — Sacituzumab govitecan as a second-line treatment for extensive stage small cell lung cancer showed promising antitumor activity and had manageable safety, according to research presented at ESMO Congress.
“Sacituzumab govitecan demonstrated promising efficacy as second-line treatment for extensive stage [small cell lung cancer (SCLC)] in patients with prior exposure to platinum-based chemotherapy along with checkpoint inhibitors,” Afshin Dowlati, MD, professor in the department of medicine, division of hematology and oncology, in Case Western Reserve University School of Medicine and associate director for clinical research at Case Comprehensive Cancer Center, said during the presentation.
Dowlati and colleagues included patients who had previously received no more than one previous line of chemoimmunotherapy with a platinum-based chemotherapy and anti-PD-L1 therapy. Patients included in the study received 10 mg/kg of sacituzumab govitecan (Trodelvy, Gilead) on days 1 and 8 of a 21-day cycle.
The researchers included 30 patients who were enrolled on or before April 27, 2023. Among these patients, the median age was 67 years, 87% had an ECOG performance status of 1 and the median duration of treatment was 3.9 months.
Dowlati and colleagues found that among the patients included in the efficacy analysis, the overall response rate was 37% and the clinical benefit rate was 40%.
In the safety analysis, the researchers found that 93% experienced a treatment-related adverse event of any grade. No treatment-related adverse events led to discontinuation of the study treatment at the time of the presentation, and no deaths had occurred due to adverse events.
“These results, we believe, are encouraging in extensive-stage SCLC,” Dowlati said during the presentation. “The trial is ongoing, with further results hopefully early next year with a full cohort, and we believe that further investigation of this drug in SCLC is warranted.”
Collapse
Dowlati A, et al. Abstract 1990MO. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Read more about
Click Here to Manage Email Alerts